

Resource Summary Report

Generated by [RRID](#) on Sep 9, 2026

Recombinant Anti-CTLA4 antibody [CAL49]

RRID:AB_2905652

Type: Antibody

Proper Citation

Abcam Cat# ab237712, RRID:AB_2905652

Antibody Information

URL: http://antibodyregistry.org/AB_2905652

Proper Citation: Abcam Cat# ab237712, RRID:AB_2905652

Target Antigen: CTLA-4

Host Organism: rabbit

Clonality: recombinant monoclonal

Comments: Applications: IHC-P, Flow Cyt (Intra), WB, IP

Antibody Name: Recombinant Anti-CTLA4 antibody [CAL49]

Description: This recombinant monoclonal targets CTLA-4

Target Organism: mouse, human

Clone ID: CAL49

Antibody ID: AB_2905652

Vendor: Abcam

Catalog Number: ab237712

Record Creation Time: 20231110T031503+0000

Record Last Update: 20260829T024112+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-CTLA4 antibody [CAL49].

No alerts have been found for Recombinant Anti-CTLA4 antibody [CAL49].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 18 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Cheng M, et al. (2026) Gut Microbiota-Induced CTLA4 Expression on CD8 + T Cells Impairs Antitumor Immunity and Promotes Colorectal Cancer Progression. Immunology, 178(3), 455.

Zhou J, et al. (2026) Gut microbiota-derived indole-3-lactic acid suppresses anti-PD-1 efficacy in esophageal squamous cell carcinoma. Cell host & microbe, 34(4), 639.

Oka T, et al. (2025) Langerhans Cells Directly Interact with Resident T Cells in the Human Epidermis. JID innovations : skin science from molecules to population health, 5(1), 100324.

Oh J, et al. (2025) Spatial analysis identifies DC niches as predictors of pembrolizumab therapy in head and neck squamous cell cancer. Cell reports. Medicine, 6(5), 102100.

Hao Y, et al. (2025) Hyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma and Improves the Impact of Dual Immune Checkpoint Inhibition. Cancer immunology research, 13(2), 185.

Cao C, et al. (2024) CXCR4 orchestrates the TOX-programmed exhausted phenotype of CD8+ T cells via JAK2/STAT3 pathway. Cell genomics, 4(10), 100659.

Cao T, et al. (2024) Cancer SLC6A6-mediated taurine uptake transactivates immune checkpoint genes and induces exhaustion in CD8+ T cells. Cell, 187(9), 2288.

Zhou Y, et al. (2024) Neuromedin U receptor 1 deletion leads to impaired immunotherapy response and high malignancy in colorectal cancer. iScience, 27(7), 110318.

Landwehr LS, et al. (2024) Expression and Prognostic Relevance of PD-1, PD-L1, and CTLA-4 Immune Checkpoints in Adrenocortical Carcinoma. The Journal of clinical endocrinology and metabolism, 109(9), 2325.

Baars MJD, et al. (2024) Multiplex spatial omics reveals changes in immune-epithelial crosstalk during inflammation and dysplasia development in chronic IBD patients. iScience, 27(8), 110550.

Li J, et al. (2024) Biomarkers of Pathologic Complete Response to Neoadjuvant Immunotherapy in Mismatch Repair-Deficient Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(2), 368.

Yousuf S, et al. (2023) Spatially Resolved Multi-Omics Single-Cell Analyses Inform Mechanisms of Immune Dysfunction in Pancreatic Cancer. *Gastroenterology*, 165(4), 891.

Qin Y, et al. (2023) A cancer-associated fibroblast subtypes-based signature enables the evaluation of immunotherapy response and prognosis in bladder cancer. *iScience*, 26(9), 107722.

Mascharak S, et al. (2023) Desmoplastic stromal signatures predict patient outcomes in pancreatic ductal adenocarcinoma. *Cell reports. Medicine*, 4(11), 101248.

Liu Z, et al. (2023) Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma. *Cancer cell*, 41(11), 1852.

Huang X, et al. (2023) Multi-kingdom gut microbiota analyses define bacterial-fungal interplay and microbial markers of pan-cancer immunotherapy across cohorts. *Cell host & microbe*, 31(11), 1930.

Li J, et al. (2023) Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer. *Cancer cell*, 41(6), 1152.

Hailemichael Y, et al. (2022) Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. *Cancer cell*, 40(5), 509.